Elotuzumab, Lenalidomide, Bortezomib, Dexamethasone, and ASCT for Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Lancet Haematol 2024 Feb 01;11(2)e101-e113, EK Mai, H Goldschmid, K Miah, U Bertsch, B Besemer, M Hänel, J Krzykalla, R Fenk, J Schlenzka, M Munder, J Dürig, IW Blau, S Huhn, D Hose, A Jauch, C Kunz, C Mann, N Weinhold, C Scheid, R Schroers, I von Metzler, A Schieferdecker, J Thomalla, P Reimer, R Mahlberg, U Graeven, S Kremers, UM Martens, C Kunz, M Hensel, A Benner, A Seidel-Glätzer, KC Weisel, MS Raab, HJ SalwenderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.